How starting a GLP-1 medicine changes food reactions and choices.
Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
We will see if starting a GLP-1 medication changes how adults with overweight or obesity react to food and the foods they choose.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Penn State University Academic / other |
| Locations | 1 site (State College, Pennsylvania) |
| Trial ID | NCT06843512 on ClinicalTrials.gov |
What this trial studies
Adults with overweight or obesity who are newly prescribed a GLP-1 medication are enrolled and tested either before or within two weeks of starting the drug and again after three months. Researchers collect measures of food reactivity and selection using behavioral tasks and the Health, Ingestive Behavior, and Technology Laboratory facilities, possibly including virtual-reality food-choice simulations. The study excludes people with prior cognitive or physical disabilities, dyslexia, epilepsy, or limited English fluency, and does not include those already on GLP-1 for more than two weeks or taking compound GLP-1 medications. Data are intended to describe changes in attitudes toward food and patterns of nutrient selection during the early course of GLP-1 treatment.
Who should consider this trial
Good fit: Adults aged 18 or older with a BMI over 25 who were prescribed a GLP-1 medication within the past two weeks, fluent in English, and without prior cognitive or physical disability are ideal candidates.
Not a fit: People under 18, those without overweight or obesity, those already on GLP-1 for more than two weeks or using compound GLP-1s, non-English speakers, or those with prior cognitive or physical disabilities are unlikely to be eligible or benefit from this protocol.
Why it matters
Potential benefit: If successful, the findings could help clinicians and patients maintain appropriate nutrient balance and make better food choices while using GLP-1 medications.
How similar studies have performed: Previous research shows GLP-1 drugs commonly reduce appetite and shift food preferences, but few studies have measured detailed real-time food choice or virtual-reality–based behavior during the first months of treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (18+) with overweight or obesity (BMI \>25 kg/m2) * Not currently taking an incretin-based medication at baseline * Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia) * Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Fluent in English Exclusion Criteria: * Adults (18+) without overweight or obesity * \<18 years of age at time of testing * Adults not taking a GLP-1 Medication * Adults taking a compound GLP-1 * Adults on GLP-1 medication for longer than 2 weeks at baseline * Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Not fluent in English
Where this trial is running
State College, Pennsylvania
- Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University — State College, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Travis Masterson — The Pennsylvania State University
- Study coordinator: Christina M Blackmon
- Email: cmb8633@psu.edu
- Phone: 425-499-8049
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.